MOPA -- Media, All-In-One Agency, Blockchain Development
Social Media/Email
  • WORK
  • NEWS
  • SERVICE
  • CONTACT

BIOSHIN raised $60M to advance neuroscience pipeline in Asia-Pacific

9/29/2020

0 Comments

 
Picture
BioShin Logo
Source: Biohaven,PRnewsWire
Sept. 29.2020, Shanghai

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, "Biohaven") announced today that BioShin Limited ("BioShin") its Asia-Pacific Subsidiary, has closed a $60M Series A investment round. The financing was led by OrbiMed, with participation from Cormorant Asset Management LLC, HBM Healthcare Investments Ltd, Surveyor Capital (a Citadel Company), and Suvretta Capital Management, LLC.
​The company named Donnie McGrath as BioShin President and Executive Chairman, and Karl Lintel as BioShin Chief Executive Officer. Also appointed Vlad Coric and Donnie McGrath of Biohaven, and David Wang of OrbiMed to Board of Directors.
Currently, BioShin is initiating NURTEC ODT Phase 3 study for acute migraine in China and Korea, and China registrational study of troriluzole in Spinocerebellar Ataxia in 4Q20.
Picture
Donnie McGrath MD, President and Executive Chairman of BioShin
The Series A funds will be used to build out BioShin in China and advance the Biohaven clinical portfolio in the Asia-Pacific region, including the imminent start of the NURTEC™ ODT (rimegepant) Phase 3 study for the acute treatment of migraine in China and Korea. BioShin also plans to initiate sites in China to participate in the global registrational trial of troriluzole in Spinocerebellar Ataxia (SCA). BioShin expects to begin both Asia-Pacific studies in the fourth quarter of 2020. BioShin has rights to the Biohaven portfolio for the entire Asia-Pacific region excluding Japan. After the transaction, Biohaven remains the majority shareholder of BioShin.

Donnie McGrath MD, President and Executive Chairman of BioShin, stated, "This investment marks an important partnership between Biohaven and these leading investors to advance Biohaven's innovative product candidates to patients in the Asia-Pacific region. BioShin now has the funding to independently advance the lead pipeline assets without relying upon Biohaven to fund these efforts in Asia-Pacific. Migraine, neurologic and neuropsychiatric diseases represent a significant medical and social burden in the Asia-Pacific region, and we are pleased to be joined by several renowned investors who support our shared vision of advancing the Biohaven portfolio in the region."
Picture
David Wang, MD, PhD, Partner at OrbiMed Asia
Picture
Karl Lintel, Chief Executive Officer of BioShin
David Wang, MD, PhD, Partner at OrbiMed Asia, commented, "We are excited about the potential of Biohaven's product portfolio in China and the broader Asia region.  We look forward to seeing continued progress by Donnie, Karl and the rest of the impressive team Biohaven has put together to help patients here in Asia." 

Karl Lintel has been appointed as Chief Executive Officer of BioShin, from his current role of Chief Operating Officer. Previous to BioShin, Lintel served as the President and General Manager China of Bristol-Myers Squibb from 2014 to 2018 and VP/General Manager of BMS Middle East and Africa from 2010 to 2014. From 1989 to 2010, he worked in a variety of roles within Pfizer Inc. across Asia, the Middle East, Europe and Global headquarters.

BioShin also announces its Board of Directors to include Donnie McGrath, Chief of Corporate Strategy and Business Development at Biohaven, to serve as the Executive Chairman, joined by Vlad Coric (CEO of Biohaven) and David Wang MD, PhD (Partner, OrbiMed).

Cooley LLP acted as counsel for the Series A investors. Locke Lord LLP acted as counsel for Biohaven.

Picture
Biohaven Logo
​
About BioShin
BioShin Limited, a privately-held biopharmaceutical company with offices in Shanghai, is advancing the Biohaven clinical portfolio in the Asia-Pacific region. BioShin holds rights to the Biohaven portfolio for all of the Asia-Pacific Region, including Australia and New Zealand, excluding Japan. Biohaven is a majority shareholder in BioShin.

About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, Rutgers and ALS Biopharma LLC and. Our progress is fueled by an entrepreneurial organizational structure and an impressive range of experience in drug development along with the confident support of top-tier biopharma investors. Currently, Biohaven's lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulator platforms. Biohaven's common shares are listed on the New York Stock Exchange and traded under the ticker symbol BHVN.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    News WorldWide

    MOPA
    ​Media, 
    All-In-One Agency, Blockchain Development

    Online Service

    ​Media
    ​Branding
    ​Celebrity Content
    ​Cultural Exchange
    Digital Marketing
    Public Relations
    Makeup
    Blockchain Project

    Our location:
    ​
    Auckland, ​New Zealand​
    Brisbane, Australia
    Shanghai, China
    Singapore


    Email:  info@mopa1.com
    Picture
     

    Archives

    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    April 2021
    March 2021
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    August 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    October 2016
    November 2014
    August 2014
    July 2014
    April 2014
    March 2014
    February 2014
    October 2013
    September 2013
    June 2013

    Categories

    All
    Asia Pacific
    Australia
    Brazil
    Chile
    China
    Cuba
    Japan
    Latin America
    Mexico
    Singapore
    United States
    Venezuela
    Vietnam

    RSS Feed

Powered by Create your own unique website with customizable templates.